Non-Toxigenic Clostridioides difficile Strain E4 (NTCD-E4) Prevents Establishment of Primary C. difficile Infection by Epidemic PCR Ribotype 027 in an In Vitro Human Gut Model
Authors:
- Perezimor EtifaPEPerezimor Etifa
- César RodríguezCRCésar Rodríguez
- Céline HarmanusCHCéline Harmanus
- Ingrid M. J. G. SandersISIngrid M. J. G. Sanders
- Igor A. SidorovISIgor A. Sidorov
- Olufunmilayo A. MohammedOMOlufunmilayo A. Mohammed
- Emily SavageESEmily Savage
- Andrew R. TimmsATAndrew R. Timms
- Jane FreemanJFJane Freeman
- Wiep Klaas SmitsWSWiep Klaas Smits
- Mark H. WilcoxMWMark H. Wilcox
- Simon D. BainesSBSimon D. Baines
Open Access
- 22 February 2023
- journal article
- research article
- Published by MDPI AG in Antibiotics
- Vol. 12 (3) , 435
Abstract
Clostridioides difficile infection (CDI) remains a significant healthcare burden. Non-toxigenic C. difficile (NTCD) strains have shown a benefit in preventing porcine enteritis and in human recurrent CDI. In this study, we evaluated the efficacy of metronidazole-resistant NTCD-E4 in preventing CDI facilitated by a range of antimicrobials in an in vitro human gut model. NTCD-E4 spores (at a dose of 107) were instilled 7 days before a clinical ribotype (RT) 027 (at the same dose) strain (210). In separate experiments, four different antimicrobials were used to perturb gut microbiotas; bacterial populations and cytotoxin production were determined using viable counting and Vero cell cytotoxicity, respectively. RT027 and NTCD-E4 proliferated in the in vitro model when inoculated singly, with RT027 demonstrating high-level cytotoxin (3-5-log10-relative units) production. In experiments where the gut model was pre-inoculated with NTCD-E4, RT027 was remained quiescent and failed to produce cytotoxins. NTCD-E4 showed mutations in hsmA and a gene homologous to CD196-1331, previously linked to medium-dependent metronidazole resistance, but lacked other metronidazole resistance determinants. This study showed that RT027 was unable to elicit simulated infection in the presence of NTCD-E4 following stimulation by four different antimicrobials. These data complement animal and clinical studies in suggesting NTCD offer prophylactic potential in the management of human CDI.Keywords
Funding Information
- Centre for Agriculture, Food and Environmental Management Research (CAFEM)
This publication has 78 references indexed in Scilit:
- Evolutionary History of the Clostridium difficile Pathogenicity LocusGenome Biology and Evolution, 2013
- Short-Term Genome Stability of Serial Clostridium difficile Ribotype 027 Isolates in an Experimental Gut Model and Recurrent Human DiseasePLOS ONE, 2013
- Bile Acid Recognition by the Clostridium difficile Germinant Receptor, CspC, Is Important for Establishing InfectionPLOS Pathogens, 2013
- Characterization of a Stable, Metronidazole-Resistant Clostridium difficile Clinical IsolatePLOS ONE, 2013
- Evaluation of an Oral Suspension of VP20621, Spores of Nontoxigenic Clostridium difficile Strain M3, in Healthy SubjectsAntimicrobial Agents and Chemotherapy, 2012
- Ribosomal multilocus sequence typing: universal characterization of bacteria from domain to strainMicrobiology, 2012
- Clinical Clostridium difficile: Clonality and Pathogenicity Locus DiversityPLOS ONE, 2011
- Tolevamer Is Not Efficacious in the Neutralization of Cytotoxin in a Human Gut Model of Clostridium difficile InfectionAntimicrobial Agents and Chemotherapy, 2009
- Effects of Exposure of Clostridium difficile PCR Ribotypes 027 and 001 to Fluoroquinolones in a Human Gut ModelAntimicrobial Agents and Chemotherapy, 2009
- The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genomeNature Genetics, 2006